Comparative study between the efficacy of topical sildenafil and topical minoxidil in the treatment of male androgenic alopecia

QJM ◽  
2021 ◽  
Vol 114 (Supplement_1) ◽  
Author(s):  
Ali Abdulkareem Al-Shabkhon ◽  
Adel Ahmed Halim Emam ◽  
Ahmed Abd Elfattah Afify
Keyword(s):  
Hair Loss ◽  
Treated Group ◽  
Treatment Modalities ◽  
Androgenic Alopecia ◽  
Men And Women ◽  
Female Pattern Hair Loss ◽  
Topical Minoxidil ◽  
Temporal Side ◽  
Male Patients ◽  
Incidence Increase

Abstract Background Androgenic alopecia is the most common form of alopecia in men and women. Its incidence increase with age, many treatment modalities are available but results are variable. Androgenetic alopecia is a hereditary thinning of the hair induced by androgens in genetically susceptible men and women. Also known as male-pattern hair loss or common baldness in men and female-pattern hair loss in women. Thinning of hair usually begins between 12 and 40 years old in males and females. Inheritance is polygenic. Aim of the study To evaluate and compare the efficacy, safety and side effects of topical sildenafil and topical minoxidil in the treatment of androgenic alopecia Patients and methods This exploratory pilot study included 30 male patients suffering from androgenic alopecia. Included patients were divided into 2 equal groups based on treatment received; one group received 1% topical sildenafil and the other group received 55 topical minoxidil. Assessment of treatment response was done using trichoscopy. Results Sildenafil treated group showed statistically significant increase in VH and TH count at 18 cm point, 24 cm point after treatment compared to before treatment. While, temporal side showed statistically significant increase in VH only. minoxidil treated group showed statistically significant increase in TH count, T/V hair ratio and hair thickness at 18 cm point and temporal side after treatment compared to before treatment. VH count was significantly decreased after treatment compared to before treatment at 18 cm point. At 24 cm point, only TH was significantly increased after treatment compared to before treatment.

scholarly journals Pharmacological therapeutics in androgenetic alopecia

2020 ◽  
Vol 63 (5) ◽  
pp. 277-285
Author(s):  
Doyoung Kim ◽  
Sujin Park
Keyword(s):  
Hair Loss ◽  
Treatment Options ◽  
Daily Intake ◽  
Androgenetic Alopecia ◽  
Men And Women ◽  
Reductase Inhibitors ◽  
Female Pattern Hair Loss ◽  
Evidence Quality ◽  
Topical Minoxidil ◽  
Current Guidelines

Androgenetic alopecia (AGA) is the most common type of hair loss and affects both men and women. Male pattern hair loss shows characteristic frontal recession and vertex baldness, whereas female pattern hair loss produces diffuse alopecia over the mid-frontal scalp. AGA is mediated by increased androgen susceptibility in affected scalp hairs. 5α-Reductase converts testosterone into dihydrotestosterone, a potent androgen, in the scalp. Both androgen receptors and 5α-reductase have higher expression levels in the balding scalp than in non-affected regions. Increased androgen susceptibility induces hair follicle miniaturization, which leads to the progressive loss of thicker terminal hairs in the balding scalp. Currently, topical minoxidil and oral 5α-reductase inhibitors, such as finasteride and dutasteride, are approved options for the pharmacological treatment of AGA. Topical minoxidil remains the mainstay of therapy for mild to moderate AGA in both men and women. The daily intake of 1-mg finasteride or 0.5-mg dutasteride shows better efficacy than topical minoxidil in regard to hair regrowth in male AGA. Anti-androgens can be used in female AGA wit clinical and biochemical evidence of hyperandrogenism. Patients may be overwhelmed and confused by the variety of treatment options for AGA management, including over-the-count drugs with low evidence quality. Therefore, physicians must be aware of the current guidelines for the management of AGA based on evidence-based approaches to select better options for patients.

scholarly journals A randomised trial of 5% minoxidil versus combination of 5% minoxidil and oral spironolactone in treatment of female pattern hair loss

2019 ◽  
Vol 5 (4) ◽  
pp. 668
Author(s):  
Nachiket Madhukarrao Palaskar ◽  
Nitin Dinkar Chaudhari ◽  
Garima Laxminarayan Balpande ◽  
Swapna Subhash Khatu
Keyword(s):  
Combination Therapy ◽  
Hair Loss ◽  
Tertiary Care ◽  
Randomised Trial ◽  
Life Questionnaire ◽  
Care Hospital ◽  
Female Pattern Hair Loss ◽  
Group I ◽  
Topical Minoxidil ◽  
Group Ii

<p class="abstract"><strong>Background:</strong> Female pattern hair loss (FPHL) is a common form of nonscarring hair loss. We compared the usefulness and safety of topical minoxidil alone with combination of oral spironolactone and topical minoxidil in the treatment of FPHL.</p><p class="abstract"><strong>Methods:</strong> This prospective, single-centre, randomised open label study over 100 patients attending tertiary care hospital in Mumbai during period December 2011 to June 2012. The data were entered into SPSS version 21 for analysis. Data collected were coded and described as frequency and percentage for qualitative data and means and standard deviation for quantitative data. Statistical analysis was done using chi-square and student t test. Statistical significance was considered if p value was less than 0.05.<strong></strong></p><p class="abstract"><strong>Results:</strong> There were 48 patients in Group I and 46 patients in Group II. At 6 months, significantly higher mean Sinclair grade was observed among Group I patients as compared to Group II patients (2.85±0.68 vs 2.56±0.50, p=0.02). We observed a significant improvement in women’s androgenetic alopecia quality of life questionnaire in Group I patients at 12 months after treatment (26.93±2.25 vs 23.47±2.95, p&lt;0.001). Minoxidil and spironolactone were tolerated well by the patients.</p><p class="abstract"><strong>Conclusions:</strong> Combination therapy of topical minoxidil and oral spironolactone has an additive effect. However, plateau of effectiveness of the combination therapy in normoandrogenic patients at 6 months of therapy was observed. We recommend the combination for 6 months and continuation of therapy with minoxidil only.</p>

scholarly journals Skin care physicians insight on epidemiological patterns, diagnosis and treatment modalities for female pattern hair loss

2020 ◽  
Vol 7 (1) ◽  
pp. 11
Author(s):  
Krishna Rajesh Kilaru ◽  
Suhasini Attada ◽  
Pooja Munnangi ◽  
Manogna Chowdary Kilaru
Keyword(s):  
Side Effects ◽  
Hair Loss ◽  
Treatment Guidelines ◽  
Age Of Onset ◽  
Platelet Rich Plasma ◽  
Diagnosis And Treatment ◽  
Treatment Modalities ◽  
Common Side Effect ◽  
Medication Cost ◽  
Female Pattern Hair Loss

<p class="abstract"><strong>Background:</strong> Female pattern hair loss (FPHL) is a common cause of hair loss in women characterized by a diffuse reduction in hair density over the crown and frontal scalp with retention of the frontal hairline. The underlying pathophysiology is multifactorial. There are no universally agreed treatment guidelines available. The objective of the study was to understand the diagnosis and treatment pattern of female pattern hair loss and the role of minoxidil topical formulation and its combination in the management of FPHL.</p><p class="abstract"><strong>Methods: </strong>Predesigned questionnaire on FPHL was prepared based on review of literature and was filled by 80 consultant dermatologists. Recorded data was statistically analyzed.</p><p class="abstract"><strong>Results: </strong>Common age of onset of FPHL was between 20 to 30 years. Majority (96.25%) have reported FPHL in association with psychological morbidity. The most preferred treatment in mild and severe FPHL was minoxidil 5% and platelet rich plasma (PRP) plus minoxidil respectively. Most dermatologists (47.5%) treated with minoxidil for over 6 months. Majority (27.5%) reported flaking as the most common side effect with minoxidil followed by dryness, scalp irritation and itching. Majority (27.5%) observed that long treatment duration was contributing to non-compliance followed by medication cost and side effects. Majority of the dermatologists (90%) felt the need for treatment guidelines in the current Indian scenario.</p><p class="abstract"><strong>Conclusions: </strong>Minoxidil was the most common preferred treatment for mild and severe FPHL. PRP is the most common choice of combination therapy with minoxidil. Minimizing side effects, patient education and universal treatment guidelines can help manage FPHL better.  </p>

Hair loss: a clinical update

2019 ◽  
Vol 8 (9) ◽  
pp. 422-429
Author(s):  
Lucy Millar-Hume ◽  
Farah Ali
Keyword(s):  
Hair Loss ◽  
Androgenic Alopecia ◽  
Levels Of Evidence ◽  
Female Pattern Hair Loss ◽  
Male Pattern

Hair loss is classified into non-scarring and scarring alopecias, the latter being further subdivided into primary and secondary forms. These classifications are also referred to as non-cicatricial and cicatricial hair loss. This article focuses on androgenic alopecia (AGA) and will, at times, be referred to as male pattern hair loss (MPHL) or female pattern hair loss (FPHL). Essentially, AGA is a non-scarring, benign form of alopecia, generally related to ageing and where, on the whole, a proportion of hair can grow back. Aestheticians should be prepared to answer a patient's questions and concerns and be familiar with the current levels of evidence surrounding the myriad of treatments available.

scholarly journals DEVELOPMENT OF THE EMULGE LFOR THE ANDROGENIC ALOPECIA TREATMENT

2020 ◽  
Vol 5 ◽  
pp. 82-91
Author(s):  
Inna Yarema ◽  
Marianа Fedorovska ◽  
Natalia Polovko
Keyword(s):  
Hair Loss ◽  
Mechanical Stability ◽  
Later Life ◽  
Acid Value ◽  
Potassium Sorbate ◽  
Androgenic Alopecia ◽  
Sophora Japonica ◽  
Female Pattern Hair Loss ◽  
Semi Solid ◽  
Biopharmaceutical Properties

Androgenic alopecia (AGA) is the most common alopecia that is heritable, androgen-dependent and occurs in both sexes with defined patterns such as Male pattern hair loss in men and Female pattern hair loss in women. AGA affects at least 50 % of men by the age of 50 years, and up to 70 % of all males in later life. The aim.The research was aimed to substantiate the optimal concentration of excipients and active pharmaceutical ingredients (APIs) of the emulgel intended for the topical treatment of androgenic alopecia. Materials and methods. In this study the samples of the emulgel bases containing different carbomer Ultrez10 concentrationsin the range of 0.3–0.6 % and its neutralizers (0.1 % of potassium sorbate and 0 % or 0.2 % of triethanolamine) were used. Colloidal and thermal stability, pH, rheological properties (structural viscosity, mechanical stability, degree of thixotropy) of these samples were determined. The emulgel samples with different percentages of the Serenoa repens dry extract and the Sophora japonica tincture were used in the biopharmaceutical studies. The samples of the emulgel with the antioxidant butylhydroxytoluene different concentrations (0 %, 0.01 %, 0.02 %, 0.03 %) were used to determine acid value during 1 year of the emulgel storage. Results and discussion. It was experimentally substantiated the optimal ratio of the emulgel ingredients that provide good APIs release and necessary consumer properties of the semi-solid remedy like application compliance, safety and storage stability. Conclusions. Physicochemical, rheological and biopharmaceutical properties of emulgel bases have been studied. It was found that the base №2 (in which the concentrations of Carbomer Ultraz 10, potassium sorbate and triethanolamine are 0.3 %, 0.1 %, 0.2 % respectively) possessed the optimal properties. Considering the results of the complete range of experimental research it was developed the final formulation of the emulgel intended for AGA treatment which included the concentration of the APIs, neutralizers, preservatives, antioxidant and fragrance.

scholarly journals Non-surgical options to treat androgenic alopecia

2021 ◽  
Vol 20 (11) ◽  
Author(s):  
Mazin Abdalla
Keyword(s):  
Laser Therapy ◽  
Hair Loss ◽  
Low Level Laser Therapy ◽  
Androgenic Alopecia ◽  
Men And Women ◽  
Hormonal Factors ◽  
Low Level ◽  
Low Level Laser ◽  
Level Laser ◽  
Surgical Options

Androgenic alopecia (AGA) is the commonest cause of hair loss in men and women. It is attributed to genetic and hormonal factors. This paper aims to discuss three non-surgical options to assess their use and effectiveness in treating AGA. This will include the following treatments: Minoxidil, Finasteride and low-level laser therapy (LLLT). Key words: Androgenic alopecia, Minoxidil, Finasteride, low-level laser therapy (LLLT)

Sign in / Sign up

Export Citation Format

Share Document